Avastin (bevacizumab) 400 mg/16 mL concentrate for solution for infusion — original (Roche, Germany) Treatment of metastatic colorectal cancer Targeted cancer therapy. Drug delivery from Europe and beyond, within 4-5 days. +380996042415, Viber, WhatsApp.

Indications

Treatment of metastatic colorectal cancer in adult patients in combination with fluoropyrimidine-based chemotherapy.

Treatment of metastatic breast cancer in adult patients:

First-line treatment in combination with paclitaxel;

First-line treatment in combination with capecitabine (when treatment with other chemotherapy regimens, including taxanes or anthracyclines, is considered inappropriate). Patients who have received taxane- and anthracycline-based regimens in the adjuvant setting within the past 12 months should not receive Zirabev in combination with capecitabine.

Treatment of adult patients with unresectable advanced, metastatic, or recurrent non-small cell lung cancer, except for predominantly squamous cell histology:

 first-line treatment in combination with platinum-based chemotherapy.

 Treatment of adult patients with advanced and/or metastatic renal cell carcinoma:

 first-line treatment in combination with interferon alfa-2a.

 Treatment of advanced (FIGO stages III B, III C, and IV) epithelial ovarian cancer, Fallopian tube and primary peritoneal cancer in adult patients:

 First-line treatment in combination with carboplatin and paclitaxel

 Treatment of first relapse of epithelial ovarian, fallopian tube, and primary peritoneal cancer sensitive to platinum-based therapy in combination with carboplatin and paclitaxel in adult patients who have not received prior therapy with bevacizumab or other VEGF inhibitors. Treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer refractory to platinum-based therapy in combination with topotecan or pegylated liposomal doxorubicin in adult patients who have received no more than two prior chemotherapy regimens or agents targeting the VEGF receptor. Treatment of persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin or alternatively paclitaxel and topotecan in adult patients who cannot receive platinum-based therapy.